Objective To investigate the expression of caspase-3 in xenograft that was treated with targeted therapy with magnetic nanoparticles in nude mice. Methods QBC939 cell lines were injected into nude mice subcutaneously to establish the model of human cholangiocarcinoma xenograft. After two weeks of tumor inoculation, the animal models were divided randomly into 4 groups: group A received placebo (sodium chloride), group B were treated with magnetic nanoparticles (250 mg/kg), group C were treated with magnetic nanoparticles (150 mg /kg) combined with inner-stent, group D with magnetic nanoparticles (250 mg /kg) combined with inner-stent (the inner-stent was used to generate the magnetic targeting effect). The 21th day after treatment, expression of caspase-3 in tumor cells of each groups were measured with histochemical method and RT-PCR. Results The quantity of caspase-3 in tumor cells that were treated with magnetic nanoparticles (250 mg/kg) combined with inner-stent was the most (P＜0.05), and the quantity of caspase-3 in cells of group C was significantly more than that of the other two groups (P＜0.05). While the quantity of caspase-3 in group B was more than that of the control group(P＜0.05). Conclusion The use of magnetic nanoparticles combined with inner-stent may increase the expression of caspase-3, and the expression is dose-dependent with magnetic nanoparticles.
Esophageal cancer is a common malignant tumor of the digestive system, with the characteristics of high incidence and poor prognosis. Traditional treatment methods cannot bring long-term prognosis to patients, and postoperative recurrence and metastasis are also the main causes of treatment failure. With the continuous development of nanomedicine, nanoparticle drug delivery, as a new treatment method, has received extensive attention. The Fe3O4 magnetic nanoparticles due to its unique superparamagnetism and biocompatibility in the treatment of esophageal cancer research in a series of exciting progress has been made. In this paper, the Fe3O4 magnetic nanodrug delivery system for the treatment of esophageal cancer is reviewed.